Latest Breaking News On - Blue owl healthcare opportunities - Page 1 : comparemela.com

Context Therapeutics Announces $100 Million Private Placement

Financing includes new and existing leading healthcare investors

United statesGina mangiaracinaPiper sandlerJennifer minai azaryExchange commissionGreat point partnersNextech invest ltdCompany nasdaqContext therapeutics incAlly bridge groupAvidity partnersBlackstone multi asset investingBlue owl healthcare opportunitiesDeep track capitalDriehaus capital managementSecurities act

Form 8-K Korro Bio, Inc For: Apr 17

Form 8-K Korro Bio, Inc For: Apr 17
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomRock springsPiper sandlerRam aiyarKendall squareKorro bio incAtlas ventureExchange commissionSecurities exchangeSecurities exchange actZip codeSecurities actExchange actMaterial definitive agreementDeep track capital

Korro Bio (KRRO) Announces $70M Placement

Korro Bio (KRRO) Announces $70M Placement
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPiper sandlerAtlas ventureKorro bio incKorro bioDeep track capitalBlue owl healthcare opportunitiesRock springs capitalTri locum partnersSecurities act

TORL secures $158m for oncology pipeline development

Clinical-stage biotechnology company TORL BioTherapeutics has announced the closure of an oversubscribed $158m Series B-2 financing round.

Mark allesBristol myers squibbPerceptive xontogeny venture fundDeep track capitalPerceptive advisorsGoldman sachs alternativesMoore strategic venturesVertex venturesBlue owl healthcare opportunitiesAvidity partners

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline

$158M Series B-2 Financing led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management,.

Dave licataVince ruizRibociclib kisqaliMark allesPalbociclib ibranceDennis slamonPerceptive xontogeny venture fundSlamon research laboratoryBristol myers squibbDivision of hematology oncologyRoth zabelCrandon lawDavid geffen school of medicineDeep track capitalPerceptive advisorsAvidity partners